Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Desmopressin for reversal of Antiplatelet drugs in Stroke due to Haemorrhage (DASH)

Next Previous
Trial Profile

Desmopressin for reversal of Antiplatelet drugs in Stroke due to Haemorrhage (DASH)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 25 Jul 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Desmopressin (Primary)
  • Indications Cerebral haemorrhage; Ischaemic stroke
  • Focus Therapeutic Use
  • Acronyms DASH

Most Recent Events

  • 01 Jul 2023 Results assessing the feasibility of randomising patients on antiplatelet drug therapy with spontaneous intracerebral haemorrhage to desmopressin or placebo to reduce the antiplatelet drug effect published in the Lancet Neurology
  • 04 Jul 2022 Status changed from active, no longer recruiting to completed.
  • 04 Apr 2022 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top